Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NSE India Stock Exchange  >  Sun Pharmaceutical Industries Ltd.    SUNPHARMA   INE044A01036

SUN PHARMACEUTICAL INDUSTRIES LTD.

(SUNPHARMA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
581.45(c) 596.55(c) 594.7(c) 582.9(c) 575.2(c) Last
7 414 570 5 500 391 5 182 972 4 546 393 5 591 688 Volume
-3.78% +2.60% -0.31% -1.98% -1.32% Change
More quotes
Financials
Sales 2021 343 B 4 697 M 4 697 M
Net income 2021 32 879 M 451 M 451 M
Net cash position 2021 54 351 M 745 M 745 M
P/E ratio 2021 35,1x
Yield 2021 0,50%
Sales 2022 378 B 5 176 M 5 176 M
Net income 2022 57 550 M 789 M 789 M
Net cash position 2022 90 702 M 1 243 M 1 243 M
P/E ratio 2022 23,9x
Yield 2022 0,61%
Capitalization 1 380 B 18 909 M 18 911 M
EV / Sales 2021 3,87x
EV / Sales 2022 3,41x
Nbr of Employees 36 000
Free-Float 44,1%
More Financials
Company
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows: - generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment; - other (6%) : primarily active pharmaceutical ingredients. At the end of March 2020, the group had 43 production plants... 
Read more
More about the company
Notations Surperformance© of Sun Pharmaceutical Industries Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about SUN PHARMACEUTICAL INDUSTRIES LTD.
01/07LUPIN : Gets US FDA Approval for Bacterial Infection Treatment Drug
MT
01/05SUN PHARMACEUTICAL INDUSTRIES : Pharma to announce third quarter results on Janu..
AQ
01/05SUN PHARMACEUTICAL INDUSTRIES : Pharma announces initiation of Phase 2 Clinical ..
AQ
2020Sensex, Nifty end at all-time high as Reliance, TCS gain
RE
2020Indian shares end at all-time high as Reliance, TCS gain
RE
2020SUN PHARMACEUTICAL INDUSTRIES : Pharma reports Q2FY21 results
AQ
2020Indian Indices Close Higher on Wednesday; State Bank of India's Fiscal Q2 Pro..
MT
2020Sun Pharma Records Sharp Jump in September Quarter Net Profit
MT
2020Indian Indices End Deep in Green on Tuesday; Sun Pharmaceutical Rises 4%
MT
2020Nifty, Sensex end higher as financials rally, factory data firms
RE
2020SUN PHARMACEUTICAL INDUSTRIES LTD. : Half-year results
CO
2020SUN PHARMACEUTICAL INDUSTRIES : Pharma Announces 5-Year Sustained Efficacy and S..
AQ
2020SUN PHARMACEUTICAL INDUSTRIES LTD. : half-yearly earnings release
2020SUN PHARMACEUTICAL INDUSTRIES : Pharma announces the launch of ILUMYA for treatm..
AQ
2020SUN PHARMACEUTICAL INDUSTRIES, INC. : Issues Voluntary Nationwide Recall of RIOM..
BU
More news
News in other languages on SUN PHARMACEUTICAL INDUSTRIES LTD.
2020SUN PHARMACEUTICAL INDUSTRIES LTD. : Veröffentlichung des Halbjahresergebnisses
2020SUN PHARMACEUTICAL INDUSTRIES LTD. : publication des résultats semestriels
2020Novartis obtient une décision favorable d'un tribunal US sur Gilenya
2020Novartis begrüsst Entscheidung von US-Gericht zu Gilenya (fingolimod)
2020SUN PHARMACEUTICAL INDUSTRIES LTD. : Veröffentlichung des Jahresergebnisses
More news
Analyst Recommendations on SUN PHARMACEUTICAL INDUSTRIES LTD.
More recommendations
Analysis
India's auto and pharma sectors not ready to wean off China
Chart SUN PHARMACEUTICAL INDUSTRIES LTD.
Duration : Period :
Sun Pharmaceutical Industries Ltd. Technical Analysis Chart | SUNPHARMA | INE044A01036 | MarketScreener
Technical analysis trends SUN PHARMACEUTICAL INDUSTRIES LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 607,23 INR
Last Close Price 575,20 INR
Spread / Highest target 33,9%
Spread / Average Target 5,57%
Spread / Lowest Target -27,0%
EPS Revisions
Managers and Directors
NameTitle
Dilip Shantilal Shanghvi Managing Director & Executive Director
Israel Makov Non-Executive Chairman
C. S. Muralidharan Chief Financial Officer
Atanu Roy SVP & Chief Information Officer
Sudhir Vrundavandas Valia Non-Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SUN PHARMACEUTICAL INDUSTRIES LTD.-2.90%18 909
OTSUKA HOLDINGS CO., LTD.-0.11%23 059
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.-4.17%18 748
ONO PHARMACEUTICAL CO., LTD.-1.71%14 692
ZHEJIANG NHU COMPANY LTD.21.59%13 575
DIVI'S LABORATORIES LIMITED-7.74%12 893
Categories
Free services
Mobile App
SOLUTIONS
About
Stock Market Quotes Interactive brokers The best of tweets Stock Market News Börse: Aktien, Kurse und Nachrichten
Copyright © 2021 Surperformance. All rights reserved. Stock quotes are provided by Factset, Morningstar and S&P Capital IQ